Nature Communications (Jun 2021)
P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas
Abstract
Chimeric antigen receptor (CAR) T cell therapy has been proposed as a promising approach for treating glioblastoma. Here the authors show that p32 is expressed in murine and human glioma and that p32-directed CAR-T cells promote anti-tumor responses in preclinical models by targeting glioma cells and tumor derived endothelial cells.